Abstract
The evolution of research on drug protein binding is discussed with the unbound concentration (Cu) and the unbound fraction (fu) as protagonists. Particular attention is paid to the mechanisms via which alterations in binding affect the pharmacokinetics (PK) and the effect, or independently the pharmacodynamics (PD). Apart from albumin, the important α-acid glycoprotein (AGP), as well as specific drug classes and applications in the clinic and development (routine monitoring, cancer and HIV therapy, allometry) are addressed. The flaws with the classical method of indirectly calculating the Cu or the unbound PK/PD parameters, based on the fu in vitro, are related to the intrinsic complexity and variability in the outcomes. Increased focus is urged on directly estimating the unbound PK/PD and also on using population statistical methods.
Keywords: Unbound drug, protein binding, AGP variability, PK/PD
Current Pharmaceutical Design
Title: The Role of Unbound Drug in Pharmacokinetics/Pharmacodynamics and in Therapy
Volume: 12 Issue: 8
Author(s): Rosario Calvo, John C. Lukas, Monica Rodriguez, Nerea Leal and Elena Suarez
Affiliation:
Keywords: Unbound drug, protein binding, AGP variability, PK/PD
Abstract: The evolution of research on drug protein binding is discussed with the unbound concentration (Cu) and the unbound fraction (fu) as protagonists. Particular attention is paid to the mechanisms via which alterations in binding affect the pharmacokinetics (PK) and the effect, or independently the pharmacodynamics (PD). Apart from albumin, the important α-acid glycoprotein (AGP), as well as specific drug classes and applications in the clinic and development (routine monitoring, cancer and HIV therapy, allometry) are addressed. The flaws with the classical method of indirectly calculating the Cu or the unbound PK/PD parameters, based on the fu in vitro, are related to the intrinsic complexity and variability in the outcomes. Increased focus is urged on directly estimating the unbound PK/PD and also on using population statistical methods.
Export Options
About this article
Cite this article as:
Calvo Rosario, Lukas C. John, Rodriguez Monica, Leal Nerea and Suarez Elena, The Role of Unbound Drug in Pharmacokinetics/Pharmacodynamics and in Therapy, Current Pharmaceutical Design 2006; 12 (8) . https://dx.doi.org/10.2174/138161206776055967
DOI https://dx.doi.org/10.2174/138161206776055967 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives
Current Medicinal Chemistry Stressed to Death: Targeting Endoplasmic Reticulum Stress Response Induced Apoptosis in Gliomas
Current Pharmaceutical Design Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design Integrative Analysis of Dysfunctional Modules Driven by Genomic Alterations at System Level Across 11 Cancer Types
Combinatorial Chemistry & High Throughput Screening Targeting 5-Lipoxygenase for Prevention and Treatment of Cancer
Current Enzyme Inhibition Janus Nano- and Microparticles as Smart Drug Delivery Systems
Current Pharmaceutical Biotechnology Passive Smoking and Coronary Heart Disease
Current Vascular Pharmacology Molecular Design and Medicinal Applications of Nano-Nitric Oxide Delivery Systems
Current Medicinal Chemistry Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Current Cancer Drug Targets BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry The Impact of CRISPR/Cas9-Based Genomic Engineering on Biomedical Research and Medicine
Current Molecular Medicine Proteasome Inhibitors Therapeutic Strategies for Cancer
Recent Patents on Anti-Cancer Drug Discovery Design and Synthesis of Novel Schiff Base-Benzothiazole Hybrids as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Peptide-Based Nanostructures for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Induction and Escalation Therapies in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis
Recent Patents on Drug Delivery & Formulation